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Abstract. Background/Aim: We aimed to clarify the clinical
effect of Korean Red ginseng administered with adjuvant
chemotherapy on the immune function of patients with bile
duct or pancreatic cancer. Patients and Methods: This was
a prospective, randomized controlled trial conducted at a
single tertiary center. Twenty-six consecutive patients who
underwent curative resection for bile duct or pancreatic
cancer followed by 5-fluorouracil/leucovorin or gemcitabine
chemotherapy were included. They were randomized 1:1 to
the ginseng and control groups. Immune and inflammatory
markers were assayed in peripheral blood samples during
and after chemotherapy. Results: Intergroup differences in
immune-related parameters before and during chemotherapy
were not significant. After chemotherapy, the percentage of
CD4+ T lymphocytes was significantly higher in the ginseng
group than in the control group (42.01% vs. 33.69%,
p=0.048). The ratio of CD4+/CD8+ T lymphocytes was also
higher in the ginseng group (2.03 vs. 1.28, p=0.027).
Neutropenia and liver dysfunction prevalence did not differ
between the groups. Conclusion: The ginseng group, which
received Korean Red ginseng daily during adjuvant
chemotherapy, showed higher levels of CD4+ T lymphocytes
and CD4+/CD8+ T lymphocyte ratio after chemotherapy.
One of the strategies employed by cancer cells to develop
treatment resistance is to suppress cellular antitumor
immunity. Recent studies have shown that naturally
occurring or tumor-induced regulatory T cells and immature
myeloid cells including myeloid-derived suppressor cells
down-regulate immune surveillance and antitumor immunity
and create an immunosuppressive environment in the host
(1-4). Therefore, to achieve a potent antitumor effect, such
immunosuppressive factors need to be overcome. 
Natural compounds derived from plants, such as
ginsenosides, have been gaining interest as promising
candidates for development as anticancer agents owing to their
low toxicity and antiangiogenic properties. Korean Red ginseng
is derived from Panax ginseng Meyer by steaming and is one
of the most widely used medicinal herbs in Asia and North
America (5). It is composed of saponins including ginsenosides
and polysaccharides (6-8). Ginsenosides are known to have
beneficial effects on cardiovascular and immune functions in
addition to possible chemoprotective and therapeutic effects in
vitro and in vivo (9-11). Korean Red ginseng is also known to
enhance T cell proliferation and cytokine secretion by
inhibiting the immunosuppressive activity of myeloid-derived
suppressor cells (12). Given this background, our study aimed
at clarifying the effect of Korean Red ginseng administered
with adjuvant chemotherapy on immune function in patients
with bile duct or pancreatic cancer.
Patients and Methods
Study design. This was a prospective, randomized controlled trial
performed at a single tertiary hospital from January 2012 to January
2016. The trial was approved by the institutional review board of
Gangnam Severance Hospital, Yonsei University College of
Medicine, Korea (3-2011-0233). Written informed consent was
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obtained from all participants. In all, 26 consecutive patients who
underwent curative resection for bile duct or pancreatic cancer
followed by adjuvant chemotherapy were included. The enrolled
patients were categorized into the ginseng or control groups in a 1:1
ratio (Figure 1). Patients were excluded from the trial under specific
conditions: 1) preoperative chemotherapy or radiotherapy, 2)
palliative resection, 3) failure to take the Korean Red ginseng, 4)
failure to visit regularly after operation.  
Intervention. A regimen comprising 5-fluorouracil/leucovorin or
gemcitabine alone was used as adjuvant chemotherapy for bile duct or
pancreatic cancer. Folinic acid (20 mg/m2) was administered as an
intravenous bolus followed by an intravenous bolus of fluorouracil
(425 mg/m2) on 3 consecutive days every 21 days. Gemcitabine (1,000
mg/m2) was infused over 30 min once a week for 3 out of 4 weeks.
Each regimen was administered to the patients for 6 cycles. 
The ginseng group received 3 g of Korean Red ginseng (Korea
Ginseng Corporation, Seoul, Republic of Korea) daily as a pill. The
dosage of 3 g/day was decided based on the safety dose from
previous reports (13, 14). Peripheral blood sampling was performed
thrice during the study period: before the initiation of adjuvant
chemotherapy, during chemotherapy, and after the end of
chemotherapy (Figure 2). Immune-related markers including CD4+
T lymphocytes; CD8+ T lymphocytes; immunoglobulins G, A, and
M; absolute neutrophil count; and total lymphocyte count were
evaluated. To assess the toxic effects of Korean Red ginseng, the
prevalence of adverse events was investigated using the Common
Terminology Criteria for Adverse Events v4.0. 
Statistical analysis. The target sample size was calculated to have
80% power with a type I error rate of 0.05 and a dropout rate of
10%. Incremental differences between the two groups were based on
a previous study, reporting 1.5 fold higher levels of anti-
inflammatory cytokines in the ginseng group in colorectal cancer
(13). All analyses were conducted in the per-protocol population.
Statistical analyses were performed using SPSS software, version
21.0 (SPSS Inc., Chicago, IL, USA). Categorical variables were
analyzed using Chi-square tests or Fisher’s exact tests, and
continuous variables were analyzed using Student’s t-tests. A p-value
of <0.05 was considered statistically significant. 
Results
Patient demographics. Baseline characteristics of the
enrolled patients are listed in Table I. Intergroup differences
regarding sex, age, body surface area, location of cancer, and
intravenous chemotherapy regimen were not significant. 
Immune and inflammatory parameters in peripheral blood
samples. Comparison of immune-related parameters revealed
no difference between the two groups before and during the
period of adjuvant chemotherapy. However, after
chemotherapy, the percentage of CD4+ T lymphocytes was
higher in the ginseng group (ginseng vs. control=42.0% vs.
33.7%, p=0.048) (Table II). Further, the ratio of CD4+/CD8+
T lymphocytes was not significantly different before and after
chemotherapy between the groups. Nevertheless, the ratio of
CD4+/CD8+ T lymphocytes showed an increasing trend and a
decline after chemotherapy in the ginseng and control groups,
respectively. Moreover, after chemotherapy, the ratio of
CD4+/CD8+ T lymphocytes was higher in the ginseng group
(ginseng vs. control=2.0 vs. 1.3, p=0.027) (Figure 3). 
Adverse events during adjuvant chemotherapy. To evaluate
the toxicity of ginseng administered during adjuvant
chemotherapy, the prevalence of adverse events during
chemotherapy was determined. The number of patients with
neutropenia of a grade higher than 3, granulocyte colony-
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Figure 1. Flow diagram of patient enrollment. Three patients were excluded from the data analysis due to failure to maintain chemotherapy or
incomplete laboratory data. 
stimulating factor use, or elevations in aspartate
aminotransferase or alanine aminotransferase of a grade
higher than 3 were not different between the two groups.
Moreover, no difference in the number of neutropenic
episodes or granulocyte colony-stimulating factor injections
was observed between the two groups (Table III).  
Discussion
In this study, we aimed to determine the clinical effect of
Korean Red ginseng as an immune-modulating agent in
patients undergoing adjuvant chemotherapy for bile duct or
pancreatic cancer. Compared to the control group, the
ginseng group showed a higher percentage of CD4+ T
lymphocytes after chemotherapy. Furthermore, the ratio of
CD4+/CD8+ T lymphocytes after chemotherapy was higher
in the ginseng group.   
Genetic or epigenetic disarrangements because of
inflammation are known to cause angiogenesis, metastasis,
and remodeling to malignant features, which leads to cancer
progression (15-17). Korean Red ginseng is heat-processed
ginseng prepared by the repeated processes of steaming and
drying of fresh ginseng (18). It has been known to undergo
changes in its types and concentrations of chemical
Kim et al: Immune-modulating Effect of Korean Red Ginseng
1897
Table I. Patient demographics.
                                           Ginseng group      Control group      p-Value
                                                   n (%)                    n (%)
Gender
  Male                                       8 (61.5)                8 (61.5)             1.000
  Female                                   5 (38.5)                5 (38.5)                  
Age (years)
  Mean (SD)                          62.2 (11.2)            62.8 (9.2)            0.880
BSA (kg/m2)
  Mean (SD)                          1.70 (0.19)           1.67 (0.21)           0.650
Location of cancer
  Pancreas                                 7 (53.8)                6 (46.2)             1.000
  Bile duct                                6 (46.2)                7 (53.8)                  
Chemotherapy regimen
  Gemcitabine                        10 (76.9)               8 (61.5)             0.673
  FL chemotherapy                  3 (23.1)                5 (38.5)                  
BSA: Body surface area; FL: 5-fluorouracil/leucovorin.
Figure 2. Study scheme.
Figure 3. Comparison of the ratio of CD4+/CD8+ T lymphocytes
between the two groups. This figure shows the ratio of CD4+/CD8+ T
lymphocytes before and after chemotherapy in the two groups. The
Ginseng group had a significantly higher ratio of CD4+/CD8+ T
lymphocytes after chemotherapy compared to the control group. 
constituents such as ginsenosides during the steaming
process (19). Many researchers have attempted to identify
the clinical benefits of Korean Red ginseng in terms of
antitumor activity, neuroprotective effect, and management
of immune system and cardiovascular disorders (20-23).
Korean Red ginseng has been reported to have immune-
modulating properties, whereby it could enhance T-cell
proliferation, suggesting it can regulate cellular immune
responses (24, 25). 
A dynamic balance in the CD4+/CD8+ ratio is crucial for
maintaining stable immune function (26). CD3+ T cells play
a central role in the cellular immune response of the host and
are divided into CD4+ helper T cells and CD8+ cytotoxic T
cells. These cells boost immune responses via the secretion
of lymphatic factors by CD4+ helper T cells and induce other
lymphatic cells crucial for an antitumor effect. Therefore, a
decrease in the number of CD4+ T cells is associated with a
weakened immune function, whereas a decrease in the
number of CD8+ cytotoxic T cells, which inhibit CD4+ and
B cell function, enhances antibody formation and cellular
immune responses (27). 
A decreased CD4+/CD8+ ratio has been reported to be
correlated with decreased immune function (28, 29). Wang
et al. showed that patients with non-small cell lung cancer
had a significantly lower CD4+/CD8+ ratio than healthy
controls and patients with advanced-stage cancer had a
significantly lower CD4+/CD8+ ratio than those with early-
stage cancer (27). In the present study, the ginseng group
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Table II. Comparison of immune-related parameters between the two groups.
                                                                                               Ginseng group (n=12)                              Control group (n=11)                            p-Value
                                                                                                        (mean, SD)                                               (mean, SD)                                          
Before chemotherapy
   Absolute neutrophil count (103/μl)                                              3.5 (1.4)                                                    3.0 (1.8)                                        0.445
   C-reactive protein (mg/l)                                                             5.5 (11.6)                                                   5.2 (7.7)                                        0.939
   Total lymphocyte count (103/μl)                                                  2.1 (0.5)                                                    1.0 (0.6)                                        0.625
   AST (IU/l)                                                                                    24.8 (8.0)                                                 33.8 (22.2)                                      0.185
   ALT (IU/l)                                                                                   20.2 (15.2)                                               31.2 (25.1)                                      0.186
   IgG (mg/dl)                                                                              1,274.9 (254.6)                                        1,396.9 (459.3)                                  0.370
   IgA (mg/dl)                                                                                246.0 (56.2)                                             264.9 (88.3)                                     0.521
   IgM (mg/dl)                                                                                113.4 (71.9)                                               96.1 (45.3)                                      0.471
   CD4+ T lymphocytes (%)                                                           43.0 (7.9)                                                 36.1 (11.6)                                      0.125
   CD8+ T lymphocytes (%)                                                           25.9 (8.4)                                                 28.8 (12.4)                                      0.509
   CD4+/CD8+ T lymphocyte ratio                                                  1.9 (0.9)                                                    1.5 (0.8)                                        0.225
During chemotherapy
   Absolute neutrophil count (103/μl)                                              3.1 (1.8)                                                    3.0 (1.0)                                        0.822
   C-reactive protein (mg/l)                                                              1.3 (1.5)                                                    2.6 (3.7)                                        0.318
   Total lymphocyte count (103/μl)                                                  2.0 (0.6)                                                    1.8 (0.6)                                        0.723
   AST (IU/l)                                                                                   26.9 (10.5)                                               28.6 (15.1)                                      0.743
   ALT (IU/l)                                                                                   23.6 (18.6)                                               29.5 (23.6)                                      0.490
   IgG (mg/dl)                                                                              1,289.0 (217.3)                                        1,362.8 (210.9)                                  0.388
   IgA (mg/dl)                                                                                250.0 (66.4)                                             246.6 (61.0)                                     0.891
   IgM (mg/dl)                                                                               120.4 (65.3)                                              89.1 (42.6)                                      0.161
   CD4+ T lymphocytes (%)                                                           40.9 (8.2)                                                  34.6 (8.8)                                       0.090
   CD8+ T lymphocytes (%)                                                           25.8 (9.5)                                                  28.9 (8.9)                                       0.433
   CD4+/CD8+ T lymphocyte ratio                                                  1.8 (0.8)                                                    1.3 (0.6)                                        0.101
After chemotherapy
   Absolute neutrophil count (103/μl)                                              3.9 (1.2)                                                    3.6 (1.7)                                        0.670
   C-reactive protein (mg/l)                                                              3.1 (5.9)                                                   5.9 (10.2)                                       0.432
   Total lymphocyte count (103/μl)                                                  2.0 (0.6)                                                    1.8 (0.6)                                        0.828
   AST (IU/l)                                                                                    29.1 (12.)                                                 29.2 (11.5)                                      0.987
   ALT (IU/l)                                                                                   25.3 (18.7)                                               28.8 (16.6)                                      0.622
   IgG (mg/dl)                                                                             1,222.3 (221.6)                                        1,334.9 (221.4)                                  0.217
   IgA (mg/dl)                                                                               293.4 (100.7)                                           342.0 (120.9)                                    0.446
   IgM (mg/dl)                                                                               263.4 (58.1)                                             245.3 (58.3)                                     0.333
   CD4+ T lymphocytes (%)                                                           42.0 (9.6)                                                  33.7 (9.4)                                       0.048
   CD8+ T lymphocytes (%)                                                           24.1 (9.0)                                                 29.3 (11.3)                                      0.233
   CD4+/CD8+ T lymphocyte ratio                                                   2.0(0.9)                                                     1.3(0.5)                                         0.027
AST: Aspartate aminotransferase; ALT: alanine aminotransferase; Ig: immunoglobulin. Significant p-Values are shown in bold.
showed a significantly higher number of CD4+ T
lymphocytes after chemotherapy along with a higher ratio of
CD4+/CD8+ T lymphocytes. This finding demonstrates that
Korean Red ginseng may have an immune-modulating effect
and could be beneficial for patients who underwent cytotoxic
chemotherapy. 
Although this was a prospective trial, the data obtained are
preliminary and should be interpreted very carefully due to
the small number of patients enrolled and the relatively
heterogeneous baseline characteristics of the sample.
Nevertheless, to our knowledge, this is the first randomized
clinical trial investigating the effects of Korean Red ginseng
in real-world hepatobiliary or pancreatic cancer patients
undergoing adjuvant chemotherapy. We found that
simultaneous administration of Korean Red ginseng with
adjuvant chemotherapy resulted in a higher number of CD4+
lymphocytes as well as a higher ratio of CD4+/CD8+ T
lymphocytes after chemotherapy in patients with bile duct or
pancreatic cancer. Thus, the findings of this study are
noteworthy and suggest that Korean Red ginseng is a safe
alternative immune-modulating agent for use during
chemotherapy in patients with bile duct or pancreatic cancer. 
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